Evaluation of galsulfase for the treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)

Expert Opinion on Orphan Drugs

Volumn 2, Issue 4, 2014, Pages 407-417

  Lourenço, Charles Marques ^a   Giugliani, Roberto ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Drug evaluation; Enzyme replacement therapy; Galsulfase; Maroteaux Lamy syndrome; Mucopolysaccharidosis VI

Indexed keywords

GALSULFASE; IMMUNOGLOBULIN G ANTIBODY;

ANXIETY DISORDER; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPEPSIA; HUMAN; LIMB PAIN; MAROTEAUX LAMY SYNDROME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THORAX PAIN; VISUAL DISORDER;

EID: 84896981361     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2014.885833     Document Type: Article

References (57)

1. Maroteaux P, Leveque B, Marie J, Lamy M. A new dysostosis with urinary elimination of chondroitin sulfate B. Presse Med 1963;71:1849-52
2. Litjens T, Baker EG, Beckmann KR, et al. Chromosomal localization of ARSB, the gene for human N-Acetylgalactosamine-4-sulphatase. Hum Genet 1989;82:67-8
3. Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis 2010;5:5
4. Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004;144:574-80
5. McGill JJ, Inwood AC, Coman DJ, et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-A sibling control study. Clin Genet 2009;77(5):492-8
6. Furujo M, Kubo T, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI. Mol Genet Metab 2011;104(4):597-602
7. Horovitz DDG, Magalhaes TSPC, Acosta A, et al. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI. Mol Genet Metab 2013;109(1):62-9
8. Peters C, Balthazor M, Shapiro E, et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996;87:4894-902
9. Wang C, Hwu W, Lin K. Long-Term follow-up of a girl with Maroteaux-Lamy syndrome after bone marrow transplantation. World J Pediatr 2008;4:152-4
10. Herskhovitz E, Young E, Rainer J, et al. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): Long-Term follow-up. J Inherit Metab Dis 1999;22:50-6
11. Turbeville S, Nicely H, Rizzo JD, et al. Clinical outcomes following hematopoietic stem cell transplantation for the treatment ofmucopolysaccharidosis VI. Mol Genet Metab 2011;102(2):111-15
12. Friso A, Tomanin R, Salvalaio M, Scarpa M. Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol 2010;159:1082-91
13. Delgadillo V, O'Callaghan M del M, Artuch R. Genistein supplementation in patients affected by Sanfilippo disease. J Inherit Metab Dis 2011;34:1039-44
14. de Ruijter J, Valstar MJ, Narajczyk M, et al. Genistein in Sanfilippo disease: A randomized controlled crossover trial. Ann Neurol 2012;71:110-20
15. Marucha J, Tylki-Szymanska A, Jakobkiewicz-Banecka J, et al. Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-Targeted isoflavone therapy (GET IT). Am J Med Genet A 2011;155A:2257-62
16. Hopwood J, Bate G, Kirkpatrick P. Galsulfase. Nat Rev Drug Discov 2006;5:101-2
17. Available from: Http://www.accessdata. fda.gov/drugsatfda-docs/label/ 2013/125117s111lbl.pdf
18. Naglazyme [BioMarin]. Naglazyme prescribing information. 2005. Ref Type: Pamphlet. Available from: Http://www.naglazyme.com/hcp/pdfs/DosageandAdminGuide. pdf
19. Auclair D, Hopwood JJ, Brooks DA, et al. Replacement therapy in Mucopolysaccharidosis type VI: Advantages of early onset of therapy. Mol Genet Metab 2003;78:163-74
20. Harmatz P, Kramer WG, Hopwood JJ, et al. Pharmacokinetic profile of recombinant human Nacetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): A phase I/II study. Acta Paediatr Suppl 2005;94(447):61-8
21. Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Results after 48 weeks in a phase 2 open-label clinical study of recombinant human Nacetylgalactosamine 4-sulfatase. Pediatrics 2005;115(6):e681-9
22. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebocontrolled, multinational study of recombinant human Nacetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006;148:533-9
23. Harmatz P, Giugliani R, Schwartz IV, et al. Long-Term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-Acetylgalactosamine 4-sulfatase. Mol Genet Metab 2008;94:469-75
24. Hendriksz CJ, Giugliani R, Harmatz P, et al. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis 2013;36(2):373-84
25. Harmatz PR, Garcia P, Guffon N, et al. Galsulfase (Naglazyme-) therapy in infants with mucopolysaccharidosis VI. J Inherit Metab Dis 2013. [Epub ahead of print]
26. Naglazyme, INN-galsulfase, European Medicines Agency. Available from: Http://www.ema.europa.eu/ema/
27. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007;120(2):405-18
28. Doǧan M, Cesur Y, Peker E, et al. Thrombocytopenia associated with galsulfase treatment. Hum Exp Toxicol 2011;30(7):768-71
29. White JT, Argento Martell L, Prince WS, et al. Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic Naglazyme (galsulfase). AAPS J 2008;10(3):439-49
30. White JT, Martell LA, Van Tuyl A, et al. Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase). AAPS J 2008;10(2):363-72
31. Brands MM, Hoogeveen-Westerveld M, Kroos MA, et al. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase. Orphanet J Rare Dis 2013;8(1):51
32. Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet Mol Biol 2010;33(4):589-604
33. Waith JE, Vellodi A, Cleary MA, et al. Guidelines for the investigation and management of mucopolysaccharidosis type VI. Available from: Http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/ prod-consum-dh/groups/dh-digitalassets/@dh/@en/documents/digitalasset/ dh-4131929.pdf
34. Australian Government Department of Health and Aging. Guidelines for the treatment of Mucopolysaccharidosis Type VI (MPS VI) disease through the Life Saving Drugs Program. Available from: Http://www.health.gov.au/internet/main/ publishing.nsf/Content/lsdp-info/$File/mps-vi-guidelines-may-2013.pdf
35. Hwu WL, Okuyama T, But WM, et al. Current diagnosis and management of mucopolysaccharidosis VI in the Asia-Pacific region. Mol Genet Metab 2012;107(1-2):136-44
36. El Dib RP, Pastores GM. A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Focus on galsulfase. Biologics 2009;3:459-68
37. Cookson R, McCabe C, Tsuchiya A. Public healthcare resource allocation and the Rule of Rescue. J Med Ethics 2008;34(7):540-4
38. Tambuyzer E. Rare diseases, orphan drugs and their regulation: Questions and misconceptions. Nat Rev Drug Discov 2010;9(12):921-9
39. Harmatz P, Yu ZF, Giugliani R, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: Evaluation of long-Term pulmonary function in patients treated with recombinant human Nacetylgalactosamine 4-sulfatase. J Inherit Metab Dis 2010;33(1):51-60
40. Decker C, Yu ZF, Giugliani R, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human Nacetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med 2010;3(2):89-100
41. Braunlin E, Rosenfeld H, Kampmann C, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: Long-Term cardiac effects of galsulfase (Naglazyme-) therapy. J Inherit Metab Dis 2013;36(2):385-94
42. Crawley AC, Niedzielski KH, Isaac EL, et al. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Invest 1997;99:651-62
43. Wang D, Wood T, Sadilek M, et al. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: Application to newborn screening for mucopolysaccharidosis II (Hunter disease). Clin Chem 2007;53:137-40
44. Gelb MH, Turecek F, Scott CR, Chamoles NA. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis 2006;29:397-404
45. Matern D. Newborn screening for lysosomal storage disorders. Acta Paediatr Suppl 2008;97:33-7
46. Dickson P, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab 2007;91:61-8
47. Munoz-Rojas MV, Horovitz DD, Jardim LB, et al. Intrathecal administration of recombinant human N-Acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis. Mol Genet Metab 2009;99(4):346-50
48. Auclair D, Hein LK, Hopwood JJ, Byers S. Intra-Articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: Enzyme dose and interval. Pediatr Res 2006;59:538-43
49. Wang D, Eadala B, Sadilek M, et al. Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns. Clin Chem 2005;51:898-900
50. Auray-Blais C, Bhérer P, Gagnon R, et al. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI. Mol Genet Metab 2011;102:49-56
51. Uribe A, Giugliani R. Selective screening for lysosomal storage diseases with dried blood spots collected on filter paper in 4,700 high-risk colombian subjects. JIMD Rep 2013;11:107-16
52. Giugliani R. Newborn screening for lysosomal diseases: Current status and potential interface with population medical genetics in Latin America. J Inherit Metab Dis 2012;35(5):871-7
53. Auclair D, Hopwood JJ, Lemontt JF, et al. Long-Term intra-Articular administration of recombinant human N-Acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI. Mol Genet Metab 2007;91:352-61
54. Giugliani R, Carvalho CG, Herber S, de Camargo Pinto LL. Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI. Curr Pharm Biotechnol 2011;12(6):956-62
55. Azevedo AC, Schwartz IV, Kalakun L, et al. Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin Genet 2004;66(3):208-13
56. Guarany NR, Schwartz IV, Guarany FC, Giugliani R. Functional capacity evaluation of patients with mucopolysaccharidosis. J Pediatr Rehabil Med 2012;5(1):37-46
57. Giugliani R. Mucopolysacccharidoses: From understanding to treatment, a century of discoveries. Genet Mol Biol 2012;35(4 (Suppl)):924-31.